Metoject (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor needed for DNA, RNA and protein synthesis. This inhibition reduces the proliferation of rapidly dividing cells, including immune cells and certain cancer cells, and also promotes anti‑inflammatory pathways through increased adenosine release.

The dose of Metoject is individualized by the prescribing clinician based on the specific indication, patient weight, renal function and treatment response. Healthcare providers determine the appropriate amount, frequency and duration, and patients should follow the prescriber's instructions without self‑adjusting the dose.

Methotrexate is classified as teratogenic and is contraindicated during pregnancy. Women of childbearing potential must use effective contraception before, during and after treatment. Limited data exist for breastfeeding, and the drug is generally avoided because it can be excreted in milk and affect the infant.

To order Metoject, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Metoject (methotrexate) is a conventional synthetic DMARD with a well‑established efficacy and safety profile, often used as first‑line therapy. Biologic agents target specific cytokines or cell surface markers and may be reserved for patients who do not respond adequately to methotrexate. Methotrexate is less costly but requires regular monitoring for toxicity.

Metoject must be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Once removed from refrigeration, it should be used within the time frame specified by the manufacturer and kept in the original packaging to maintain stability.

Metoject is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient using aseptic technique. The volume and concentration are determined by the prescriber, and the site should be rotated to minimize local irritation.

Serious risks include bone marrow suppression leading to severe anemia or infection, hepatotoxicity that can progress to fibrosis or cirrhosis, pulmonary toxicity such as interstitial pneumonitis, and renal impairment. Patients should be educated to report unexplained fever, persistent cough, jaundice, or unusual bruising promptly.

Metoject is contraindicated in patients with known hypersensitivity to methotrexate, severe renal or hepatic impairment, active infections, and in women who are pregnant or planning pregnancy. Caution is also advised for individuals with pre‑existing blood disorders, uncontrolled diabetes, or those receiving live vaccines.